Ultragenyx Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/25/2026
- Nasdaq, S&P end lower as tech stocks fall
- Micron posts record profit as AI memory demand fuels explosive growth
- Brent settles at lowest since before start of Iran war as more tankers exit Hormuz
- All eyes on Micron earnings tonight as sell-off raises stakes for AI memory trade
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
Ultragenyx Pharma (RARE) Tops Q4 EPS by 6c, Revenues Beat
February 19, 2019 4:05 PM ESTUltragenyx Pharma (NASDAQ: RARE) reported Q4 EPS of ($1.73), $0.06 better than the analyst estimate of ($1.79). Revenue for the quarter came in at $16.3 million versus the consensus estimate of $13.65 million.
This last year was important for Ultragenyx as we successfully launched two therapies internationally and... More
